Category | Any HPV 16 positivea | Any HPV 16 and/or 18 positivea | Other HR HPV without HPV 16 and/or 18 | ||||||
---|---|---|---|---|---|---|---|---|---|
CIN 2 | CIN 3 | CIN 2/3 | CIN 2 | CIN 3 | CIN 2/3 | CIN 2 | CIN 3 | CIN 2/3 | |
OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | |
Non-Māori, 20–29 years | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Non-Māori, 30–39 years | 0.8 (0.4–1.5) | 0.5 (0.2–1.2) | 0.6 (0.4–1.1) | 0.8 (0.4–1.6) | 0.5 (0.2–1.2) | 0.6 (0.4–1.1) | 1.4 (0.7–2.9) | 2.1 (0.8–5.2) | 1.7 (0.9–3.0) |
Non-Māori, 40–69 years | 0.6 (0.3–1.5) | 0.2 (0.1–0.6) | 0.4 (0.2–0.8) | 0.5 (0.2–1.3) | 0.4 (0.1–1.1) | 0.4 (0.2–0.9) | 2.0 (0.8–5.0) | 2.2 (0.7–6.9) | 2.1 (1.1–4.3) |
Māori, 20–29 years | 0.8 (0.4–1.7) | 0.7 (0.3–1.6) | 0.7 (0.4–1.3) | 0.6 (0.3–1.4) | 0.5 (0.2–1.2) | 0.6 (0.3–1.0) | 1.7 (0.8–3.7) | 2.1 (0.8–5.4) | 1.8 (1.0–3.4) |
Māori, 30–39 years | 0.9 (0.3–2.4) | 0.4 (0.2–1.1) | 0.7 (0.3–1.3) | 1.2 (0.4–3.7) | 0.6 (0.2–1.9) | 0.9 (0.4–2.0) | 0.9 (0.3–2.6) | 1.6 (0.5–4.7) | 1.1 (0.5–2.4) |
Māori, 40–69 years | 1.4 (0.4–4.1) | 0.4 (0.1–1.9) | 0.8 (0.3–2.1) | 1.7 (0.5–5.9) | 0.8 (0.1–4.4) | 1.2 (0.5–3.3) | 0.6 (0.2–2.2) | 1.3 (0.2–7.1) | 0.8 (0.3–2.3) |
Test for interactionb | P = 0.36 | P = 0.52 | P = 0.16 | P = 0.09 | P = 0.22 | P = 0.02 | P = 0.07 | P = 0.27 | P = 0.02 |